Webbläsaren som du använder stöds inte av denna webbplats. Alla versioner av Internet Explorer stöds inte längre, av oss eller Microsoft (läs mer här: * https://www.microsoft.com/en-us/microsoft-365/windows/end-of-ie-support).

Var god och använd en modern webbläsare för att ta del av denna webbplats, som t.ex. nyaste versioner av Edge, Chrome, Firefox eller Safari osv.

Does Low-Molecular-Weight Heparin Influence the Antimyeloma Effects of Thalidomide? A Retrospective Analysis of Data from the GIMEMA, Nordic and Turkish Myeloma Study Groups

Författare

  • Meral Beksac
  • Anders Waage
  • Sara Bringhen
  • Sigurdur Y. Kristinsson
  • Gulsan Turkoz Sucak
  • Peter Gimsing
  • Giulia Lupparelli
  • Tulin Firatli-Tuglular
  • Gunnar Juliusson
  • Ingemar Turesson
  • Antonio Palumbo

Summary, in English

Background/Aim: Low-molecular-weight heparin (LMWH) has been shown to prolong survival among patients with solid tumors, but its role among myeloma patients is unknown. Patients: Data from the GIMEMA (Gruppo Italiano Malattie Ematologiche dell'Adulto), Nordic and Turkish myeloma study groups comparing melphalan and prednisolone with (MPT, n: 404) or without thalidomide (MP, n: 393) are analyzed for effects of LMWH. Forty percent (159/394) of the patients on MPT and 7.4% (29/390) in the MP arm received LMWH. Results: Thalidomide improved response and progression-free survival (PFS). Regardless of thalidomide treatment, response rate was higher among those receiving LMWH vs. none vs. other anticoagulants (58.1 vs. 44.9 vs. 50.4%, p = 0.01). PFS was significantly longer (median 32 vs. 21 and 17 vs. 17 months, p = 0.004) only among international scoring system (ISS) I patients receiving MPT +/- LMWH vs. MP +/- LMWH. The group of MPT patients who also received LMWH had a better OS compared to those who did not [45 months, 95% confidence interval (CI) 27.7-62.3, vs. 32 months, 95% CI 26.1-37.9; p = 0.034]. When multivariate analysis was repeated in subgroups, thalidomide was no longer a significant factor (response, PFS) among those receiving LMWH. Conclusion: Addition of LMWH to MPT, in particular in patients with low ISS, suggests additive effects, but the results are limited by the retrospective design of our study. (C) 2015 S. Karger AG, Basel

Avdelning/ar

Publiceringsår

2015

Språk

Engelska

Sidor

372-380

Publikation/Tidskrift/Serie

Acta Haematologica

Volym

133

Issue

4

Dokumenttyp

Artikel i tidskrift

Förlag

Karger

Ämne

  • Hematology

Nyckelord

  • Anticoagulation
  • Heparin
  • Low-molecular-weight heparin
  • Multiple
  • myeloma
  • Thalidomide

Status

Published

ISBN/ISSN/Övrigt

  • ISSN: 1421-9662